Akron on Task Force Behind New Legislation Introduced This Week in U.S. Senate

Posted on

Akron attended EBD Biotech Showcase

This week, Akron participated in the 8th annual EBD Biotech showcase, which took place from January 11-13, in San Francisco, CA.

The showcase saw an attendance of over 3,000 delegates – from private and public sector biotechnology companies to investors – all with the goal of identifying innovative new strategies, technologies and products which have the potential of significantly advancing life sciences.

Company presentations were the cornerstone of the meeting. Akron presented on the first day of the conference: Attendees learned first-hand about our brand new products, which included fully-documented, GMP-grade includes human serum albumin and virus-inactivated fibronectin. Alongside this, our custom bioassay capabilities and innovative DMSO-free cryopreservation media were also heavily featured.

If you would like to learn about our presentation and weren’t able to attend, please get in touch with us.


New U.S. legislation to support regenerative medicine introduced this week

An important milestone for the Alliance for Regenerative Medicine, which Akron Biotech is a part of, occurred this week.

U.S. Senator Tammy Baldwin just presented a new piece of legislation with profound potential impact on Regenerative Medicine. Called The Advancing Standards in Regenerative Medicine Act, it calls for the establishment of a Standards Coordinating Body in Regenerative Medicine and Advanced Therapies. This body would be responsible for the generation of standards with critical importance for the advancement, generation and manufacturing of cell therapies. The press release can be found here, and includes a statement by Michael Werner, executive director of the Alliance of Regenerative Medicine.

Akron Biotech is part of the task force behind the Standards Coordinating Body, and has long supported such initiatives which seek to foster advancements in the generation of critically-needed standards in the regenerative medicine field. The Act announced this week is an important milestone and hopefully the beginning of a significant shift toward better standards across the entire industry.

The full act can be accesssed here.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s